(Q51562143)

7 April 2018

title

Long-term Efficacy of Interferon in Severe Uveitis Associated with Behçet Disease. (English)

1 reference

7 April 2018

0 references

1 reference

5

1 reference

7 April 2018

Bahram Bodaghi

6

1 reference

7 April 2018

David Saadoun

object named as

David Saadoun

3

0 references

author name string

Eléonore Diwo

1

1 reference

7 April 2018

Julie Gueudry

2

1 reference

7 April 2018

Bertrand Weschler

4

1 reference

7 April 2018

publication date

19 August 2016

1 reference

7 April 2018

Ocular Immunology and Inflammation

published in

1 reference

7 April 2018

volume

25

1 reference

7 April 2018

issue

1

1 reference

7 April 2018

page(s)

76-84

1 reference

7 April 2018

Uveitis in Behçet disease: an analysis of 880 patients.

cites work

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Behcet's disease in Iran: analysis of 6500 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

The use of interferon alpha in Behçet disease: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Behçet's disease: ocular effects and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Role of nuclear factor-kappaB in the antiviral action of interferon and interferon-regulated gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Multicenter study of infliximab for refractory uveoretinitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Complete regression of retinal neovascularization after therapy with interferon alfa in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Immunopathogenesis of Behçet's disease with special emphasize on the possible role of antigen presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Etiopathogenesis of Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

New insights into the pathogenesis of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Epidemiology of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Interferon-associated retinopathy during the treatment of chronic hepatitis C: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

Effects of infliximab in the treatment of refractory posterior uveitis of Behçet’s disease after withdrawal of infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2016.1206204

10.1080/09273948.2016.1206204

21 January 2018

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

27541620

1 reference

7 April 2018